Aclaris Therapeutics, Inc. ACRS
4.20 USD +0.30 (+7.56%)
Nov 9, 2026, 2:29 PM EST
3.85 Day range 4.28
2.10 52-week range 6.60
- YTD
- +39.37%
- 1 year
- +80.82%
News
defenseworld.net Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
zacks.com Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
benzinga.com Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year.…- benzinga.com Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13 Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.- benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
benzinga.com Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
benzinga.com Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures rose, but Whirlpool plunged after a major earnings miss and lowered guidance; HSBC, Armstrong World and others also fell premarket.
benzinga.com Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an…
benzinga.com Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
benzinga.com Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10 Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.
benzinga.com Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
benzinga.com Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance…- benzinga.com Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares…
benzinga.com SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stocks also down in pre-market trading.
benzinga.com This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.- benzinga.com Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the…
- benzinga.com Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11 Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
benzinga.com This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.- benzinga.com Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12 Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and raises the price target from $8 to $10.
benzinga.com Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138 "These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody that has the potential to be highly effective in a variety of inflammatory and immunological disorders,"…
benzinga.com Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026 Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will…
benzinga.com Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10 Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $10.- benzinga.com Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and maintains $8 price target.
- benzinga.com Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting - Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life -WAYNE, Pa., March 27, 2026 (GLOBE…
- benzinga.com Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
benzinga.com Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of…
benzinga.com Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways 
benzinga.com Looking Into Aclaris Therapeutics Inc's Recent Short Interest - benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
benzinga.com Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.- benzinga.com Aclaris Therapeutics Announces Preclinical Results From Potent And Selective ITK/JAK3 Inhibitor ATI-2138 In Murine Model Of Severe Alopecia Areata - ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype -WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Aclaris Therapeutics Reveals Interim Results From the First-in-human Phase 1a Single and Multiple Ascending Dose Trial of ATI-052 Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052Trial Results Support Potential for Extended…
benzinga.com Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the…
- benzinga.com Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023